Simplified Aztreonam Dosing in Patients with End-Stage Renal Disease: Results of a Monte Carlo Simulation | Zendy

Alan E. Gross | Zendy; Hongmei Xu | Zendy; Diansong Zhou | Zendy; Nidal AlHuniti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Simplified Aztreonam Dosing in Patients with End-Stage Renal Disease: Results of a Monte Carlo Simulation

Author(s) -

Alan E. Gross,

Hongmei Xu,

Diansong Zhou,

Nidal AlHuniti

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01066-18

Subject(s) - dosing , aztreonam , medicine , renal function , creatinine , pharmacodynamics , pharmacokinetics , intensive care medicine , urology , pharmacology , antibiotics , chemistry , antibiotic resistance , imipenem , biochemistry

The manufacturer-recommended aztreonam dosing for patients with creatinine clearance values of <10 ml/min/1.73 m 2 is complex. It is not known whether simpler posthemodialysis dosing administered once daily or thrice weekly can reliably achieve pharmacodynamic goals. We found that 1 or 2 g administered once daily after hemodialysis had >90% probability of target attainment up to MICs of 4 or 8 mg/liter, respectively. Thrice-weekly dosing should generally be avoided, except in nonsevere infections with MICs of ≤0.5 mg/liter.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research